DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $59.91, for a total value of $101,847.00. Following the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at approximately $6,560,384.64. This represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Wednesday, April 15th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $63.04, for a total value of $107,168.00.
• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $64.85, for a total value of $110,245.00.

DexCom Stock Performance

Shares of DXCM opened at $66.95 on Wednesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a fifty day moving average price of $63.33 and a 200-day moving average price of $65.82. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market cap of $25.83 billion, a PE ratio of 28.61, a P/E/G ratio of 1.12 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the business posted $0.32 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 2.56 earnings per share for the current fiscal year.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced Dexcom Flex in Germany, expanding CGM access to a broader Type 2 diabetes population using basal insulin, oral medications, or GLP-1 therapies. Dexcom Announces Dexcom Flex in Germany
• Positive Sentiment: Bank of America lowered its price target to $80 from $100 but kept a buy rating, which still implies upside from current levels. Benzinga report on Bank of America price target
• Neutral Sentiment: Barclays reiterated its sell rating on DexCom, adding a bearish counterpoint that may limit enthusiasm. Barclays sticks to its sell rating
• Negative Sentiment: EVP Michael Jon Brown sold 1,700 shares in a pre-arranged Rule 10b5-1 transaction, which is routine but can still weigh on sentiment when investors are watching insider activity closely. SEC Form 4 filing

Institutional Investors Weigh In On DexCom

Several institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in DexCom by 32.3% in the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after buying an additional 645,534 shares during the last quarter. Centaurus Financial Inc. acquired a new stake in DexCom in the 1st quarter worth about $943,000. Tri Locum Partners LP boosted its holdings in DexCom by 65.6% in the 1st quarter. Tri Locum Partners LP now owns 698,158 shares of the medical device company’s stock worth $43,844,000 after buying an additional 276,558 shares during the last quarter. Bull Harbor Capital LLC acquired a new stake in DexCom in the 1st quarter worth about $252,000. Finally, Arkadios Wealth Advisors boosted its holdings in DexCom by 302.2% in the 1st quarter. Arkadios Wealth Advisors now owns 12,950 shares of the medical device company’s stock worth $813,000 after buying an additional 9,730 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DXCM. Benchmark began coverage on DexCom in a report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Citigroup reissued a “buy” rating and issued a $79.00 target price (down from $84.00) on shares of DexCom in a research report on Monday, May 4th. TD Cowen cut their target price on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Sanford C. Bernstein set a $77.00 target price on DexCom in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $82.21.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.